PROTAC STING degrader-4

PROTAC STING degrader-4 是一种不含硝基的共价 STING PROTAC 降解剂,DC50 为 3.23 μM,可有效抑制 STING 及其下游信号传导(如 p-TBK1、p-NF-κB (p-P65))以及免疫炎症细胞因子,并可减轻 Cisplatin (MS-E94993) 诱发的急性肾损伤 (AKI) 小鼠模型中的肾脏和血液炎症(粉色:STING 配体 (MS-Q61789);蓝色:Cereblon 配体 (MS-N78428);黑色:连接子 (MS-Y84054))。
PROTAC STING degrader-4
产品编号: MS-Z05911 纯度: 98.25% 分子式: C39H42Cl2N8O9 分子量: 837.70
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价
200mg
询价
询价

产品描述

PROTAC STING degrader-4 是一种不含硝基的共价 STING PROTAC 降解剂,DC50 为 3.23 μM,可有效抑制 STING 及其下游信号传导(如 p-TBK1、p-NF-κB (p-P65))以及免疫炎症细胞因子,并可减轻 Cisplatin (MS-E94993) 诱发的急性肾损伤 (AKI) 小鼠模型中的肾脏和血液炎症(粉色:STING 配体 (MS-Q61789);蓝色:Cereblon 配体 (MS-N78428);黑色:连接子 (MS-Y84054))。

生物实验数据

生物活性 PROTAC STING degrader-4 is a nitro-free covalent STING PROTAC degrader with a DC50 of 3.23 μM that effectively inhibits STING and its downstream signaling, such as p-TBK1 and p-NF-κB (p-P65), as well as immune inflammatory cytokines, and alleviates renal and blood inflammation in a Cisplatin (MS-E94993)-induced acute kidney injury (AKI) mouse model (pink: STING ligand (MS-Q61789); blue: Cereblon ligand (MS-N78428); black: linker (MS-Y84054)).
IC50 & Target

NF-κB

 

TBK1

 

体外研究
(In Vitro)

PROTAC STING degrader-4 (Compound 2h) (0.6-40 μM,2-72 小时) 以剂量和时间依赖性的方式降解 THP-1 dual 细胞中的 STING,持续 72 小时,其 DC50 为 3.23 μM (24小时)。
PROTAC STING degrader-4 (10 μM,48 小时) 通过蛋白酶体途径诱导 STING 降解。
PROTAC STING degrader-4 (0.3-20 μM,2 小时) 以剂量依赖性的方式降低 p-TBK1 和 p-NF-κB (p-P65) 的蛋白水平,从而抑制 STING 下游信号级联,而非直接降解 STING。
PROTAC STING degrader-4 (0.6-20 μM,2 小时) 显著且剂量依赖性地降低 IFN-β 和 CXCL10 的产生,并抑制 THP1-Dual 细胞中 IFNB1、CXCL10 和 ISG15 的 mRNA 表达。
PROTAC STING degrader-4 (0.03-30 μM,24-48 小时) 在 THP1-Dual 和 RAW-Lucia 细胞 (低于 20 μM) 以及人类和小鼠正常细胞 (低于 30 μM) 中均表现出没有或弱细胞毒性。

Western Blot Analysis

Cell Line: THP-1 dual cells
Concentration: 0.6, 1.2, 2.5, 5, 10, 20, 40 μM
Incubation Time: 2, 4, 8, 12, 24, 48, 72 h
Result: Dose-dependently degraded STING with a DC50 of 3.23 μM (24 h) in THP-1 dual cells.
Continuously reduced the expression level of STING in THP1-dual cells for 72 h in THP-1 dual cells.
Induced potent degradation of STING, and this degradation effect was not inhibited by lysosome inhibitor BAF (Bafilomycin A1) (MS-R94699) but was reversed by proteasome inhibitor MG132 (MS-L06849) Induced the degradation of STING via the proteasome pathway rather than its warhead molecule or E3 ligase ligand, BAF (a lysosome inhibitor) and MG132 (a proteasome inhibitor).

Western Blot Analysis

Cell Line: THP-1 dual cells
Concentration: 0.3, 0.6, 1.25, 2.5, 5, 10, 20 μM
Incubation Time: 2 h following MSA-2 (10 μM) for 16 h
Result: Dose-dependently reduced protein levels of p-TBK1 and p-NF-κB (p-p65), suppressing the STING downstream signaling cascade beyond direct degradation of STING.

Real Time qPCR

Cell Line: THP-1 dual cells
Concentration: 0.6, 1.25, 2.5, 5, 10, 20 μM
Incubation Time: 2 h following MSA-2 (10 μM) for 24 h
Result: Significantly and dose-dependently inhibited IFNB1, CXCL10 and ISG15 mRNA expression in THP1-Dual cells.

Cell Viability Assay

Cell Line: THP1-Dual, RAW-Lucia cells, human normal cell lines (HEK293T and WI38VA-13) and mouse normal cell lines (HT22 and MEF).
Concentration: 0.03, 0.07, 0.15, 0.31, 0.62, 1.25, 2.5, 5, 10, 20 μM (THP1-Dual and RAW-Lucia cells), 1.1, 3.3, 10, 30 μM (four human and mouse normal cell lines)
Incubation Time: 24, 48 h
Result: Did not exhibit significant inhibition of cellular viability below 20 μM in THP1-Dual and RAW-Lucia cells.
Exhibited no or weak cytotoxicity against four human and mouse cell lines at concentrations below 30 μM.
体内研究
(In Vivo)

PROTAC STING degrader-4 (Compound 2h) (30 mg/kg,腹腔注射,每日一次,持续 3 天) 通过降解 STING 和下游信号通路 (例如 p-IRF3) 显著缓解 Cisplatin 诱发的 AKI 小鼠模型中肾脏炎症。

Animal Model: Male C57BL/6 mice (8 weeks old) were given Cisplatin administration (15 mg/kg) 1 h after PROTAC STING degrader-4 to induce AKI mice model.
Dosage: 30 mg/kg
Administration: i.p., daily for 3  days and then collected blood and kidney samples after cisplatin induction1.
Result: Potently mitigated ischemic symptoms of kidneys.
Significantly reduced the protein level of STING and p-IRF3 in kidney tissues.
Effectively reduced the mRNA levels of Tnfα, Isg15 and Cxcl10.
Effectively suppressed the production of CXCL10, IFN-β, IL-6 in plasma.
性状 固体
颜色 Light yellow to light brown

化学信息

分子量 837.70
分子式 C39H42Cl2N8O9

储存&溶解度

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 100 mg/mL (119.37 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM1.1937 mL5.9687 mL11.9374 mL29.8436 mL
5 mM0.2387 mL1.1937 mL2.3875 mL5.9687 mL
10 mM0.1194 mL0.5969 mL1.1937 mL2.9844 mL
15 mM0.0796 mL0.3979 mL0.7958 mL1.9896 mL
20 mM0.0597 mL0.2984 mL0.5969 mL1.4922 mL
25 mM0.0477 mL0.2387 mL0.4775 mL1.1937 mL
30 mM0.0398 mL0.1990 mL0.3979 mL0.9948 mL
40 mM0.0298 mL0.1492 mL0.2984 mL0.7461 mL
50 mM0.0239 mL0.1194 mL0.2387 mL0.5969 mL
60 mM0.0199 mL0.0995 mL0.1990 mL0.4974 mL
80 mM0.0149 mL0.0746 mL0.1492 mL0.3730 mL
100 mM0.0119 mL0.0597 mL0.1194 mL0.2984 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础